Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2007-03-16
2011-10-04
Sullivan, Peter O (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C564S090000
Reexamination Certificate
active
08030356
ABSTRACT:
The invention relates to N-hydroxysulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxysulfonamide derivatives release NHO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of functional groups on the N-hydroxysulfonamide derivatives.
REFERENCES:
patent: 3751255 (1973-08-01), Wilson et al.
patent: 4798824 (1989-01-01), Belzer et al.
patent: 6525081 (2003-02-01), Matsumoto et al.
patent: 6936639 (2005-08-01), Wink et al.
patent: 2004/0038947 (2004-02-01), Wink et al.
patent: 2005/0153966 (2005-07-01), Gangloff et al.
patent: 2007/0299107 (2007-12-01), Toscano et al.
patent: 186456 (1966-10-01), None
patent: WO 01/10827 (2001-02-01), None
patent: WO-2005/074598 (2005-08-01), None
patent: WO-2005/074598 (2005-08-01), None
patent: WO-2007/002444 (2007-01-01), None
patent: WO-2007/109175 (2007-09-01), None
Scozzafava et al., ‘Carbonic Anhydrase and Matrix Metalloproteinase Inhibitors: Sulfonylated Amino Acid Hydroxamates with MMP Inhibitory Properties Act as Efficient Inhibitors of CA Isozymes I, II and IV, and N-Hydroxysulfonamides Inhibit Both These Zinc Enzymes’, Journal of Medicinal Chemistry, vol. 43, No. 20, 3677-3687, (2000).
Scozzafava et al., ‘Carbonic Anhydrase and Matrix Metalloproteinase Inhibitors: Sulfonylated Amino Acid Hydroxamates with MMP Inhibitory Properties Act as Efficient Inhibitors of CA Isozymes I, II and IV, and NHydroxysulfonamides Inhibit Both These Zinc Enzymes,’ Journal of Medicinal Chemistry, vol. 44, p. 1016.
Backx, P.H. (Jan. 1995). “The Relationship between Contractile Force and Intracellular [Ca2+] in Intact Rat Cardiac Trabeculae,”J. Gen. Physio.105:1-19.
Bonner, F.T. at al. (May 13, 1992). “Kinetic, Isotopic, and15N NMR Study ofN-Hydroxybenzenesulfonamide Decomposition: An HNO Source Reaction,”Inorg. Chem.31(10-13):2514-2519.
Bouzamondo A. et al. (Apr. 2001). “Beta-Blocker Treatment in Heart Failure,”Fundam. Clin. Pharmaco. 15(2):95-109.
Bristow, M.R. et al. (2001). “Inotropes and β-Blockers: Is There a Need for New Guidelines?”J. Card. Fail.7(2 Suppl. 1):8-12.
Byrnes, S. et al. (1978). “Potential Inhibitors of L-Asparagine Biosynthesis. 4. Substituted Sulfonamide and Sulfonylhydrazide Analogues of L-Asparagine,”J. Med. Chem.21(1):45-49.
Byrnes, S. et al. (Nov. 1978). “Potential Antitumor Agents via Inhibitors of L-Asparagine Synthetase: Substituted Sulfonamides and Sulfonyl Hydrazides Related to Glutamine,”J. Pharm. Sci.67(11):1550-1553.
Crawford, J.H. et al. (Jan. 15, 2006, e-pub. Sep. 29, 2005). “Hypoxia, Red Blood Cells, and Nitrite Regulate NO-Dependent Hypoxic Vasodilation,”Blood107(2):566-574.
Fukuto, J.M. et al. (May 2005, e-pub. Apr. 2, 2005). “The Physiological Chemistry and Biological Activity of Nitroxyl (HNO): The Neglected, Misunderstood, and Enigmatic Nitrogen Oxide,”Chem. Res. Toxicol.18(5):790-801.
Gao, W. D. et al. (1994). “Myofilament Ca2+Sensitivity in Intact Versus Skinned Rat Ventricular Muscle,”Circ. Res.74:408-415.
Gao, W.D. et al. (Feb. 15, 1998). “Calcium Cycling and Contractile Activation in Intact Mouse Cardiac Muscle,”J. Physiol.507(Pt.1):175-184.
Hare, J.M. et al. (Oct. 15, 1995). “Nitric Oxide Inhibits the Positive Inotropic Response to β-Adrenergic Stimulation in Humans with Left Ventricular Dysfunction,”Circulation92(8):2198-2203.
Hare, J.M. et al. (Mar. 1998). “Pertussis Toxin-sensitive G Proteins Influence Nitric Oxide Synthase III Activity and Protein Levels in Rat Hearts,”J. Clin. Invest.101(6):1424-1431.
Hart, C.Y.T. et al. (Jul. 2001). “Differential Effects of Natriuretic Peptides and NO on LV Function in Heart Failure and Normal Dogs,”Am. J. Physiol. Heart Circ. Physiol.281(1):H146- H154.
Ingall, T.J. (May 15, 2000). “Preventing Ischemic Stroke: Current Approaches to Primary and Secondary Prevention,”Postgrad. Med.107(6):34-50.
International Search Report mailed on Aug. 22, 2007, for PCT Application No. PCT/US2007/006710 filed on Mar. 16, 2007, seven pages.
Katori, T. et al. (Feb. 4, 2005, e-pub. Dec. 9, 2004). “Calcitonin Gene-Related Peptide In Vivo Positive Inotropy Is Attributable to Regional Sympatho-Stimulation and Is Blunted in Congestive Heart Failure,”Circ. Res.96(2):234-243.
Lowes, B.D. et al. (Mar. 2000). “Inotropes in the Beta-Blocker Era,”Clin. Cardiol.23(Suppl. III):III-11-III-16.
Ma, X.L. et al. (Dec. 7, 1999). “Opposite Effects of Nitric Oxide and Nitroxyl on Postischemic Myocardial Injury,”Proc. Natl. Acad. Sci. USA96(25):14617-14622.
Mincione, F. et al. (1998). “Carbonic Anhydrase Inhibitors: Inhibition of Isozymes I, II and IV withN-Hydroxysulfonamides—a Novel Class of Intraocular Pressure Lowering Agents,”J. Enzyme Inhibition13(4):267-284.
Paolocci, N. et al. (Oct. 2000). “cGMP-Independent Inotropic Effects of Nitric Oxide and Peroxynitrite Donors: Potential Role for Nitrosylation,”Am. J. Physiol. Heart Circ. Physiol.279(4):H1982-H1988.
Rastaldo, R. et al. (Jun. 2001). “CytochromeP-450 Metabolite of Arachidonic Acid Mediates Bradykinin-Induced Negative Inotropic Effect,”Am. J. Physiol. Heart Circ. Physiol.280(6):H2823-2832.
Scozzafava, A. et al. (Oct. 5, 2000, e-pub. Sep. 13, 2000). “Carbonic Anhydrase and Matrix Metalloproteinase Inhibitors: Sulfonylated Amino Acid Hydroxamates with MMP Inhibitory Properties Act as Efficient Inhibitors of CA Isozymes I, II, and IV, andN-Hydroxysulfonamides Inhibit Both These Zinc Enzymes,”J. Med. Chem.43(20):3677-3687.
Scozzafava, A. at al. (2001, a-pub. Mar. 8, 2001). “Carbonic Anhydrase and Matrix Metalloproteinase Inhibitors: Sulfonylated Amino Acid Hydroxamates with MMP Inhibitory Properties Act as Efficient Inhibitors of CA Isozymes I, II, and IV, andN-Hydroxysulfonamides Inhibit Both These Zinc Enzymes,” Erratum,J. Med. Chem.44(6):1016.
Slotwiner-Nie, P.K. et al. (Sep. 2001). “Infectious Diarrhea in the Elderly,”Gastroenterol. Clin. N. Am.30(3):625-635.
Suzuki, T. at al. (Feb. 24, 2005). “Novel Inhibitors of Human Histone Deacetylases: Design, Synthesis, Enzyme Inhibition and Cancer Cell Growth Inhibition of SAHA-Based Non-hydroxamates,”J. Med. Chem.48(4):1019-1032.
Takahira, R. et al. (Sep. 15, 2001). “Dexamethasone Attenuates Neutrophil Infiltration In the Rat Kidney in Ischemia-Reperfusion Injury: The Possible Role of Nitroxyl,”Free Radic Biol. Med.31(6):809-815.
Thevis, M. et al. (Oct. 2001). “High Speed Determination of Beta-Receptor Blocking Agents in Human Urine by Liquid Chromatography/Tandem Mass Spectrometry,”Biomed Chromatogr.15(6):393-402.
Zamora, R. et al. (1995). “Oxidative Release of Nitric Oxide Accounts for Guanylyl Cyclase Stimulating, Vasodilator and Anti-Platelet Activity of Piloty's Acid: a Comparison with Angeli's Salt,”Biochem. J.312:333-339.
Zani, F. et al. (May 1994). “Antimicrobial and Genotoxic Properties of Quinoline Derivatives,”Bollettino Chimico Farmaceutico133(5):328-338.
Brynes et al., “Potential Antitumor Agents via Inhibitors of L-Asparagine Synthetase: Substituted Sulfonamides and Sulfonyl Hydrazides Related to Glutamine,”J. Pharm. Sci., 67(11):1550-1553 (Nov. 1978).
Brynes et al., “Potential Inhibitors of L-Asparagine Biosynthesis. 4. Substituted Sulphonamide and Sulfonylhydrazide analogues of L-Asparagine,”J. Med. Chem., 21(1):45-49 (Jan. 1978).
Database CAPlus Abstract Accession No. 1994:645157, Chemical Abstracts Service, Columbus, Ohio (1994).
Scozzafava et al., “Carbonic Anhydrase and Matrix Metalloproteinase Inhibitors: Sul
Brookfield Frederick Arthur
Cohen Andrew D.
Courtney Stephen Martin
Frost Lisa Marie
Kalish Vincent Jacob
Arnold & Porter LLP
Cardioxyl Pharmaceuticals, Inc.
Chong Suet M.
O Sullivan Peter
The Johns Hopkins University
LandOfFree
N-hydroxylsulfonamide derivatives as new physiologically... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N-hydroxylsulfonamide derivatives as new physiologically..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-hydroxylsulfonamide derivatives as new physiologically... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4258915